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Abstract: Ribonucleases are proteins whose use is promising in anticancer therapy. We have
previously constructed different human pancreatic ribonuclease variants that are selectively
cytotoxic for tumor cells by introducing a nuclear localization signal into their sequence. However,
these modifications produced an important decrease in their stability compromising their behavior
in vivo. Here, we show that we can significantly increase the thermal stability of these cytotoxic
proteins by introducing additional disulfide bonds by site-directed mutagenesis. One of these
variants increases its thermal stability by around 17 ◦C, without affecting its catalytic activity while
maintaining the cytotoxic activity against tumor cells. We also show that the most stable variant is
significantly more resistant to proteolysis when incubated with proteinase K or with human sera,
suggesting that its half-live could be increased in vivo once administered.
Keywords: antitumor protein; nuclear-directed ribonuclease; disulfide bond; thermal stability;
proteolytic resistance
1. Introduction
The increasing use of recombinant proteins for therapeutic purposes has highlighted certain
issues, such as the control of the lifetime in the bloodstream or the long-term storage of the drug,
that are related to the proteins’ stability. Maintenance of a protein drug’s native structure is not only
critical for the specific interactions with the target molecules, but also determines its solubility and
its transport in a physiological environment. Along these lines, the production of new proteins with
enhanced therapeutic abilities may be hampered by the reduction of the protein’s stability upon
introduction of the designed mutations. Using strategies aimed to increase the stability of recombinant
proteins is therefore an important issue. Among these strategies, we can mention the introduction of
additional disulfide bonds [1], prolines [2], salt bridges [3], or the sequence modification to increase
the propensity to adopt a given secondary structure [4].
Ribonucleases (RNases) are promising agents to use in anticancer therapy. RNase cytotoxicity
requires interaction with the cell membrane, which is followed by endocytosis. Then, cytotoxic RNases
are translocated to the cytosol where they evade the cytosolic RNase inhibitor (RI) and cleave the
cellular RNA inducing apoptosis [5,6]. RI is a protein that tightly binds to most pancreatic-type
RNases inhibiting them and it is thought to act as a safeguard against extracellular RNases that
could accidentally reach the cytosol [7]. We have previously shown that introducing an engineered
nuclear localization signal (NLS) into the sequence of the human pancreatic RNase (HP-RNase)
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endows this enzyme with selective cytotoxic activity against tumor cells. These RNases, called nuclear
directed-RNases (ND-RNases), are directed to the nuclear compartment which is free of RI [8]. The first
example of this strategy consisted in a cytotoxic HP-RNase variant named PE5 that was able to cleave
nuclear RNA, inducing apoptosis in tumor cells and reducing the amount of P-glycoprotein in different
multidrug-resistant cell lines [9–12]. These RNases are inhibited by the RI in vitro [9,13]. The region
of the RNase recognized by the NLS-mediated import machinery is also involved in the binding to
the RI. Consequently, either the RI or the α-importin can bind to the ND-RNase but not both at the
same time. As discussed elsewhere [14], a competence between the RI and the α-importin is stablished
inside the cell. In this situation, some ND-RNase molecules could be captured by the α-importin
and released into the nucleus. The lack of free ND-RNase molecules in the cytosol would shift the
RI:ND-RNase equilibrium toward dissociation releasing free ND-RNase, which could be captured by
the importin and released again into the nucleus. The characterization of the gene expression pattern of
PE5 treated-cells versus untreated cells has shown that this RNase affects multiple metabolic pathways
that are important for cancer development [13].
PE5 was derived from PM5 [15], a non-cytotoxic HP-RNase variant that presented a higher
thermal stability and was produced at high yields, by introducing a conformational bipartite NLS
into its structure [9,10]. However, this modification brought a decrease in the T1/2 of around 13 ◦C.
A second generation of ND-RNases was obtained by the addition to PE5 of new NLSs fused at different
sites [16]. One of these variants, termed NLSPE5, is ten times more cytotoxic than PE5 but has an even
slightly lower thermal stability that compromises its use in vivo.
To overcome this weakness, NLSPE5 has been engineered to increase its thermal stability by
introducing additional disulfide bonds. We have produced a variant that increases its thermal stability
by around 17 ◦C, slightly increasing its catalytic activity and retaining the cytotoxic activity against
tumor cells. The increase in stability resulted in a significant resistance to proteolysis when the protein
was incubated with proteinase K or with human sera.
2. Results and Discussion
2.1. Design of ND-RNase Variants with Additional Disulfide Bonds
Thermal stabilization of ND-RNases can ameliorate their anticancer properties for two reasons.
First of all, the stabilization should increase their resistance to proteolysis once they are distributed
throughout the body. It is widely recognized that proteolytic resistance is dependent on the stability
of the protein, increasing alongside its own stability [17,18]. Second, it has been described that the
thermal stability of the antitumor RNases is an important factor in their cytotoxicity, likely by limiting
their proteolytic degradation once the protein reaches the cytosol [1]. ND-RNases contain four native
disulfide bonds that tether the protein molecules, contributing to its thermal stability. The introduction
of additional disulfide bonds is an alternative for increasing the thermal stability of the protein (for a
review, see [19,20]).
Therefore, we aimed to introduce an additional disulfide bond in the ND-RNase NLSPE5.
The positions where to introduce cysteine residues in the NLSPE5 sequence in order to create a
new disulfide bond were chosen from the analysis of a modeled structure of the ND-RNase according
to the following rationale:
(1) In order to be cytotoxic the ND-RNases must interact with α-importin [10], so we excluded those
residues placed on the predicted zones of interaction of the ND-RNase with the importin; that is,
around the N-terminus of α-helix 1 of the HP-RNase, the C-terminus of α-helix 2 and into the
loop connecting β-strands 4 and 5. We also excluded those residues important for the catalytic
activity of the RNase (see Figure 1A).
(2) We then inspected the modeled structure to find residue pairs with α-carbons placed at a distance
between 5 and 7 Å. This range of distances is slightly higher than that found between the two
α-carbon atoms of the disulfide bonds of the modeled structure (between 5.2 and 5.8 Å).
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Figure 1. Design of the ND-RNase variants. (A) Location of the engineered additional disulfide bonds 
in the primary sequence of the ND-RNase. B-factor plot for each residue of the sequence (pdb 1dza). 
Orange boxes show the position of the catalytic triad of the enzyme (His12, His119 and Lys41) and 
blue boxes those of the residues important for α-importin binding (Lys1, Arg31–33 and Arg89–91). 
Engineered disulfide bonds are indicated under the plot by lines connecting the created cysteines in 
NLSPE5Cys1 (red), NLSPE5Cys2 (pink), NLSPE5Cys3 (blue), and NLSPE5Cys4 (green). (B) Ribbon 
diagram of the modeled structure of PE5 ND-RNase and detailed disposition of the different pairs of 
residues substituted by cysteine in each variant. (C) Amino acid connectivity of the five disulfide 
bonds in the most stable variant NLSPE5Cys3. Black lines correspond to the disulfide bonds already 
present in the parental RNase and blue line to the new introduced disulfide bond. 
3) Among the residue pairs following the former criteria, we investigated the relative disposition 
of their side chains. We only took into account those residue pairs that had side chains facing 
each other or that were arranged in a parallel way, and we excluded those pairs that were facing 
away from each other on the structure.  
4) We considered that it was possible the protein would have to rearrange locally when introducing 
a disulfide bond. Therefore, the introduction of the new disulfide bond between residues located 
Figure 1. Design of the ND-RNase variants. (A) Location of the engineered additional disulfide bonds
in the primary sequence of the ND-RNase. B-factor plot for each residue of the sequence (pdb 1dza).
Orange boxes show the position of the catalytic triad of the enzyme (His12, His119 and Lys41) and
blue boxes those of the residues important for α-importin binding (Lys1, Arg31–33 and Arg89–91).
Engineered disulfide bonds are indicated under the plot by lines connecting the created cysteines in
NLSPE5Cys1 (red), NLSPE5Cys2 (pink), NLSPE5Cys3 (blue), and NLSPE5Cys4 (green). (B) Ribbon
diagram of the modeled structure of PE5 ND-RNase and detailed disposition of the different pairs
of residues substituted by cysteine in each variant. (C) Amino acid connectivity of the five disulfide
bonds in the most stable variant NLSPE5Cys3. Black lines correspond to the disulfide bonds already
present in the parental RNase and blue line to the new introduced disulfide bond.
(3) Among the residue pairs following the former criteria, we investigated the relative disposition of
their side chains. We only took into account those residue pairs that had side chains facing each
other or that were arranged in a parallel way, and we excluded those pairs that were facing away
from each other on the structure.
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(4) We considered that it was possible the protein would have to rearrange locally when introducing
a disulfide bond. Therefore, the introduction of the new disulfide bond between residues located
at the most rigid regions of the protein was not a suitable strategy. This idea has been confirmed
experimentally [21] and in silico [22]. Dani and colleagues [22] analyzed previously engineered
disulfide bonds in a set of recombinant proteins where the effect on protein stability was known
and the wild type crystal structure was available. They reported that stabilizing mutations
were mostly found in regions of medium to high mobility and near the protein surface in loops
larger than 25 residues. Here, we only considered those residue pairs in which at least one of
them was placed in a highly mobile region. In the HP-RNase structure, the C-terminal region
is highly mobile (Figure 1A). Likewise, the hinge loop connecting the first alpha helix with the
rest of the protein (residues 16 to 24) also presents high mobility and indeed in some structures
could not be solved (for a review, see [23]). Therefore, residues present in these regions were
preferably considered.
According to these criteria, we selected three residue pairs to be replaced by cysteine:
Pro19–Pro101, Asn76–Thr128 and Arg104–Asp126. These residues were located at flexible regions
along the protein (Figure 1A) as indicated by their B-factors [24]. Their location in the HP-RNase
structure, and the distance and orientation of their side chains are shown in Figure 1B. As a proof of
concept of the importance of the region’s flexibility where cysteines are introduced, we also selected
two residues, Ile107 and Asp121, that despite having their lateral chains arranged in a parallel way and
a distance between both alpha-carbons of 5.45 Å (Figure 1B), they were located at positions with low
flexibility (Figure 1A). It was expected in this case that the variant displayed a lower thermal stability.
All these aforementioned residues were substituted by cysteine through site-directed mutagenesis
in order to create the variants NLSPE5Cys1, NLSPE5Cys2, NLSPE5Cys3, and NLSPE5Cys4 (see
Table 1). A one-dimensional diagram showing the amino acid connectivity of the five disulfide bonds
in NLSPE5Cys3 is shown in Figure 1C. These variants were produced in E. coli BL21 (DE3) cells in the
form of inclusion bodies, solubilized with guanidinium chloride (Gdm-Cl) and reduced glutathione
and then refolded in a buffer containing oxidized glutathione. The refolded sample was purified
through a monoS column. This purification step allowed for the separation of the ND-RNase with five
disulfide bonds from that fraction of the protein that had a lower number of disulfide bonds since in
the latter case the free cysteine residues are forming disulfide bonds with glutathione, introducing an
extra negative charge into the molecule [25]. We initially expected that the yield of purified protein of
the new variants would be lower than that of the parent protein since the presence of an additional
disulfide bond could complicate its refolding. However, the final yield of properly folded proteins
per liter of the induced culture was even higher for NLSPE5Cys3 and only lower for NLSPE5Cys4
(Table 1) compared to NLSPE5.
Table 1. Yield of purified ND-RNase carrying five disulfide bonds and their T1/2 calculated
using UV-spectrophotometry.
Name Replacements Yield 1 T1/2 2
NLSPE5 - 15 mg 23.6 ◦C
NLSPE5Cys1 Pro19–Pro101 15 mg 38.7 ◦C
NLSPE5Cys2 Asn76–Thr128 15 mg 26.1 ◦C
NLSPE5Cys3 Arg104–Asp126 30 mg 49.9 ◦C
NLSPE5Cys4 Ile107–Asp121 3 mg 29.3 ◦C
1 Yield of purified protein per L of induced culture. 2 T1/2 calculated spectrophotometrically in a buffer containing
sodium acetate pH 4.0 and 1 M Gdm-Cl.
2.2. Characterization of the Effect of the Additional Disulfide Bond on the Thermal Stability of the Variants
We investigated the change in thermal stability produced by the introduction of the cysteine
residues. We initially carried out these studies by following the unfolding of the protein when
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increasing the temperature using spectrophotometry. In the first assays, using 50 mM sodium acetate
pH 4.0, we observed that the T1/2 of NLSPE5Cys2 and NLSPE5Cys4 were very similar to that of the
parent protein NLSPE5. However, the post-transition of the denaturation curves of NLSPE5Cys1
and NLSPE5Cys3 could not be observed, although the samples were heated to the highest possible
temperature (85 ◦C). This hampered determining the T1/2 and indicated that these two proteins were
much more stable than NLSPE5. The experiments were repeated under harsher conditions with
the presence of 1 M Gdm-Cl at pH 4.0, and we could obtain the entire single transition-unfolding
curve (Figure 2). As shown in Table 1, under these experimental conditions, the T1/2 of NLSPE5Cys2
and NLSPE5Cys4 were again very similar to that of NLSPE5, whereas those of NLSPE5Cys1 and
NLSPE5Cys3 increased by 16 ◦C and 27 ◦C, respectively. We can speculate that the difference in
thermal stability between NLSPE5Cys1 and NLSPE5Cys3 could be due in part to the removal of the
two proline residues in the former variant. As in the case of the addition of disulfide bonds (see below),
the introduction of proline residues decreases the conformational entropy of the denatured state [26].
This is because the rigid pyrrolidine ring constrains the main chain dihedral ϕ angle leading to the
decrease of Cα-N rotation’s conformational freedom in the unfolded state.
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Figure 2. Te perature unfolding curves of the different variants in 1 M Gdm-Cl, 50 mM sodium acetate,
pH 4.0. Symbols: NLSPE5 ( ); NLSPE5Cys1 (#); NLSPE5Cys2 (H); NLSPE5Cys3 (∆); and NLSPE5Cys4
(). Curves were obtained monitoring the change in absorbance at 280 nm when the temperature
was increased.
For NLSPE5Cys1 and NLSPE5Cys3 and the parent NLSPE5, we also characterized their thermal
stability by DSC. This technique allowed for measuring the T1/2 in an acetate buffer at pH 5.0 without
the presence of the denaturant. For both variants, the unfolding process was completely reversible and
thus the thermodynamic parameters could be calculated, and are presented in Table 2. The significant
increase in thermal stability was confirmed in the absence of Gdm-Cl although the differences in T1/2
respective to NLSPE5 were lower than those previously stated (16.6 ◦C for NLSPE5Cys3 and 11.1 ◦C
for NLSPE5Cys1). The difference of ∆T1/2 respective to that encountered using the spectrophotometric
assay could be explained, at least in part, assuming that the effect of Gdm-Cl and a lower pH was
higher on the parent variant than on the new variants.
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Table 2. Thermodynamic parameters of the temperature unfolding of the variants at pH 5.0 using
Differential Scanning Calorimetry.
NLSPE5 NLSPE5Cys1 NLSPE5Cys3
T1/2 (◦C) 48.3 ± 0.4 59.4 ± 0.2 64.9 ± 1.0
∆Hcal (kJ/mol) 241.1 ± 1.6 273.2 ± 0.1 308.3 ± 8.4
∆∆G (kJ/mol) - −8.35 ± 0.2 −12.47 ± 0.35
Introducing disulfide bonds is thought to increase the thermal stability by limiting the entropy
of the unfolded state, thereby destabilizing the unfolded state respective to the native state [27,28].
In addition, disulfide bonds could increase the thermal stability by increasing the enthalpy of the
folded state compared to the unfolded state as a result of burying non-polar groups [29]. However,
disulfide bonds can increase or decrease the number of interactions of the folded state that contribute
to protein stability; therefore, when engineering new mutants, the effect that a precise disulfide bond
may produce in the thermal stability is difficult to predict. For example, in the homologous RNase A,
the removal of a single cystine decreases the T1/2 by around 20–36 ◦C [30], but the addition of new
cystines has been proven to have a more modest effect on T1/2, and in some cases their introduction
has even decreased it [31]. More stable variants of RNase A have been created by introducing a cystine
between residues 4 and 118 (∆T1/2 of around 5 ◦C [1]) and between residues 43 and 85 (∆T1/2 of
around 2 ◦C [31]) but the increases in stability are lower than those presented here.
2.3. Characterization of the Biological Activities of the Variants
As classically discussed by Shoichet et al., [32], the minimization of protein free energy can
produce well-packed hydrophobic interiors and hydrophilic exteriors, but can preclude the formation
of the protein active-site, where charged or polar groups are often sequestered from water or
hydrophobic patches exposed to solvent. Furthermore, alteration of the sequence of a protein can
induce a global rearrangement of the protein structure, altering the active-site cleft. For example,
the introduction of a disulfide bond between residues 4 and 118 reduced the catalytic activity of
HP-RNase by 10-fold [33] or by 3-fold in the G88R HP-RNase variant [1]. In order to investigate
whether the introduction of the cysteine residues had altered the catalytic activity of the ND-RNases,
we characterized the kinetic parameters for the hydrolysis of cytidine 2′,3′-cyclic monophosphate (C>p)
by NLSPE5 and the constructed variants. Table 3 shows that the kinetic parameters of NLSPE5Cys1 and
NLSPE5Cys2 are very similar to those of the parent NLSPE5. Surprisingly, NLSPE5Cys3, the variant
with the higher stability, increases its catalytic efficiency compared to the parent NLSPE5. Finally,
the catalytic activity and KM of NLSPE5Cys4 were clearly altered and thus the catalytic efficiency of
this variant is around 12-fold lower than that of the parent variant. It can be postulated that, in this case,
the formation of the extra disulfide bond has produced a rearrangement of the protein architecture,
which significantly alters the active site conformation.
Table 3. Catalytic parameters for the hydrolysis of C>p of the different ND-RNase variants.
Parameter
ND-RNase Variant
NLSPE5 NLSPE5Cys1 NLSPE5Cys2 NLSPE5Cys3 NLSPE5Cys4
Kcat (min−1) 413 ± 191 695 ± 131 480 ± 48 573 ± 7 139 ± 41
KM (mM) 0.88 ± 0.53 1.34 ± 0.11 1.44 ± 0.27 0.65 ± 0.15 4.08 ± 0.51
Relative Kcat/KM (%) 100 ± 7.7 134.8 ± 14.6 88.9 ± 25.4 233.1 ± 49.3 8.8 ± 1.5
The cytotoxic activity of the RNases is exerted through a multi-step mechanism (for a review,
see [5]) in which the RNase must not only be catalytically active but must also be able to cross the
cellular membrane, evade the cytosolic RNase inhibitor and resist proteolysis while it is endocytosed.
Therefore, maintenance of ribonucleolytic activity in the constructed variants did not necessarily mean
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that they had maintained their cytotoxic activity since other parameters could have been altered due to
the residue substitutions. Hence, we investigated the effect of the mutations on the cytotoxic activities
of the variants respective to NLSPE5 on two different human cell lines: NCI-H460 lung cancer cell
line and OVCAR-8 ovarian cancer cell line. In accordance with their catalytic activity parameters,
NLSPE5Cys4 was between 30 and 45-fold less cytotoxic than the parent variant whereas the rest of
the variants displayed the same cytotoxic activity as NLSPE5 (Table 4). The effect of the different
ND-RNases was similar in both cell lines.
Table 4. IC50 values (µM) of the different ND-RNases on OVCAR-8 and NCI-H460 cell lines.
Cell Line NLSPE5 NLSPE5Cys1 NLSPE5Cys2 NLSPE5Cys3 NLSPE5Cys4
OVCAR-8 0.2 ± 0.1 0.3 ± 0.2 0.4 ± 0.2 0.2 ± 0.1 6.9 ± 3.8
NCI-H460 0.2 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 9.2 ± 4.3
2.4. Resistance of the Variants to Proteolysis
Proteolytic degradation of protein-based drugs is seen as a major weakness limiting their
therapeutic application. Since protein stabilization and resistance to proteolysis are intimately related,
we investigated the effect of proteases on the variants compared to NLSPE5.
Resistance to proteolysis was first checked by incubating the different variants with proteinase K
at 37 ◦C for over 90 min. Samples were withdrawn at varying times, analyzed through SDS-PAGE and
the percentage of intact protein was quantified respective to the initial state (Figure 3). This allowed us
to measure the half-life of the protein in the reaction, that is, the time required to cleave 50% of the
ND-RNase molecules, which corresponded to around 7.5 min for NLSPE5 and NLSPE5Cys4, 14.5 min
for NLSPE5Cys2, 18.2 min for NLSPE5Cys1 and 21 min for NLSPE5Cys3.
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Proteases are ubiquitous constituents of cells, tissues and body fluids. Specifically, the bloodstream
contains proteases participating in hemostasis, fibrinolysis, and tissue conversion, among other
activities. We also checked the proteolytic resistance of the most resistant variants, NLSPE5Cys1
and NLSPE5Cys3, when incubated with human sera at 37 ◦C for 92 h. Two different sera from healthy
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volunteers were used. Again, the percentage of intact protein compared to the initial moment was
quantified using densitometric analysis of SDS-PAGE gels (Figure 4). NLSPE5 and NLSPE5Cys1 were
partially cleaved after 3–6 h of incubation at 37 ◦C, and after 100 h of incubation less than 30–60% of the
protein remained intact. In contrast, the percentage of intact NLSPE5Cys3 remained high throughout
the experiment with both sera and only around 10% of the molecules were cleaved after 100 h.
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Figure 4. Resistance to proteolysis of the most table ND-RNase vari nts when i cubated in human
sera. Amount of intact NLSPE5 (( for se um 1 and # for se um 2); NLSPE5Cys1 (H for serum 1 and ∆
for serum 2); and NLSPE5Cys3 ( for serum 1 and  for serum 2) along time when incubated in the
pres nce of two different human sera at 37 ◦C.
In conclusion, w ave designed and produced two new antitumor ND-RNases that have an
increased resistance to proteolysis without altering either its catalytic activity or its cytotoxicity for
tumor cells. NLSPE5Cys3 is the most interesting candidate among them to be analyzed in vivo as an
antitumor drug.
3. Materials and Methods
3.1. Plasmid Construction
Construction of NLSPE5 has been previously described [16]. The introduction of two additional
cysteine residues to create a disulfide bond was carried out by two successive rounds of site-directed
mutagenesis using the Quikchange method (Agilent, Santa Clara, CA, USA). Specific oligonucleotides
used to create each variant are listed in Supplementary Table S1. All constructs were confirmed by
DNA sequencing.
3.2. RNase Expression and Purification
NLSPE5 variants were produced in the form of inclusion bodies in E. coli BL21 (DE3) cells
transformed with the corresponding vector as previously described [15,25]. Briefly, ND-RNases were
solubilized from inclusion bodies with Gdm-Cl and reduced glutathione. The ND-RNases were
then refolded through drop dilution in the appropriate buffer containing oxidized glutathione and
purified through Mono-Scation-exchange chromatography (GE Healthcare, Marlborough, MA, USA).
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The molecular mass of each variant was confirmed by matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (Bruker, Billerica, MA, USA). The protein concentration of each
variant was determined by UV spectroscopy in a Lambda Bio 20 spectrophotometer (PerkinElmer,
Waltham, MA, USA), using molar extinction coefficients of 7950 M−1 cm−1 for NLSPE5 and 8075 M−1
cm−1 for the variants carrying two additional cysteines. These extinction coefficients were calculated
using the method devised by Pace et al. [34].
3.3. Spectrophotometric Determination of Thermal Stability
Temperature-unfolding studies were essentially carried out as described [35]. Proteins were
dissolved to a concentration of 0.8–1 mg/mL in 50 mM sodium acetate, pH 4.0 or in 1 M Gdm-Cl,
50 mM sodium acetate, pH 4.0. Temperature-unfolding was followed spectrophotometrically at 280 nm.
Transition curves were fitted to a two-state thermodynamic model combined with sloping linear
functions for the native and denatured states, and the thermodynamic parameters were calculated
as previously reported [36]. All data are described as the mean ± standard error (SE) of three
independent determinations.
3.4. Calorimetric Determination of Thermal Stability
Microcalorimetric measurements were carried out on a nano DSC differential scanning
microcalorimeter (TA Instruments, New Castle, DE, USA), equipped with a capillary cell, at a heating
rate of 1 K/min from 298 to 373 K and a constant pressure of 0.3 MPa. Protein solutions were
prepared at 1 mg/mL in 50 mM sodium acetate buffer at pH 5.0. The heating curves were corrected
for an instrumental baseline obtained by heating the solvent used for the protein solution. T1/2,
calorimetric denaturation enthalpy (∆Hcal) and free energy of unfolding (∆GT1/2) were determined as
described in [37].
3.5. Determination of Steady-State Kinetic Parameters
A spectrophotometric assay [38] was used to determine the kinetic parameters of the ND-RNase
variants for the hydrolysis of C>p (Sigma, Saint Louis, MO, USA). Steady-state kinetic parameters
were obtained from the Lineweaver-Burk plot through regression analysis. All data are described as
the mean ± SE of three independent determinations.
3.6. Cell Lines and Culture Conditions
The NCI-H460 human lung cancer cell line and the OVCAR-8 human ovarian cancer cell
line were obtained from the National Cancer Institute-Frederick DCTD tumor cell line repository.
They were routinely grown at 37 ◦C in a humidified atmosphere of 5% CO2 in RPMI (Gibco, Waltham,
MA, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco), 50 U/mL penicillin and
50 µg/mL streptomycin (Gibco). Cells remained free of Mycoplasma and were propagated according
to established protocols.
3.7. Cell Proliferation Assays
Cells were seeded into 96-well plates at 1500 cells/well for OVCAR-8, and at 1900 for
NCI-H460. After 24 h of incubation, cells were treated with various concentrations of RNase for
72 h. Drug sensitivity was determined by the MTT method essentially following the manufacturer’s
instructions (Sigma, Saint Louis, MO, USA) and according to [39]. All data are presented as the mean
± SE of at least three independent experiments with three replicates for each.
3.8. Resistance to Proteinase K
Sensitivity to proteinase K was investigated essentially as described [40]. All proteins were
prepared at a final concentration of 10 µM in 50 mM TrisHCl, 150 mM NaCl pH 8.0 and incubated
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with proteinase K recombinant PCR grade (Roche, Basel, Switzerland) at a final concentration of
0.35 µM for different times (0 to 90 min) at room temperature. PMSF (1.5 µM) was used to stop the
reaction, and samples were then analyzed by SDS-polyacrilamide gel electrophoresis (SDS-PAGE) (15%
polyacrylamide). Quantification of the intact protein in the gel was performed with ImageJ software
(Wisconsin, MA, USA) [41].
3.9. Analysis of the Proteolysis Resistance in Serum
A sample of whole blood was drawn at the Dr. Josep Trueta University Hospital of Girona from
two healthy human volunteers that had signed the informed consent. The samples were allowed to
clot, centrifuged at 2500× g for 5 min and the sera were collected in aliquots and frozen at −80 ◦C,
without heat inactivation or cryopreservation, until use. All the variants (10 µM final concentration in
PBS) were incubated at 37 ◦C with an equal volume of the different sera. Aliquots were withdrawn at
different times (0 to 100 h), mixed with Laemmli buffer and stored at −20 ◦C. Samples were analyzed
by SDS-PAGE (15% polyacrylamide). Quantification of the intact protein in the gel was performed
using Quantity One software (Bio-Rad Laboratories, Hercules, CA, USA).
Supplementary Materials: The following are available online. Table S1: List of oligonucleotides used to introduce
the different cysteine residues on the NLSPE5.
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